Stock Markets May 5, 2026 01:32 PM

Waters Rises After Q1 Beat, Lifts Full-Year Profit and Organic Growth Targets

Laboratory equipment maker posts stronger-than-expected sales and adjusted EPS, cites organic momentum and Becton Dickinson acquisition contributions

By Nina Shah WAT BDX
Waters Rises After Q1 Beat, Lifts Full-Year Profit and Organic Growth Targets
WAT BDX

Waters Corp shares jumped after the company reported first-quarter revenue and adjusted earnings that outpaced analyst estimates, and it raised both its organic constant-currency revenue growth outlook and full-year adjusted profit guidance. The results reflected strong organic performance together with contributions from an acquired business of Becton Dickinson.

Key Points

  • Waters reported Q1 revenue of $1.27 billion, beating the LSEG analyst consensus of $1.20 billion.
  • Adjusted EPS rose to $2.70, up 20% year-over-year and above the $2.34 analyst estimate.
  • Company raised 2026 organic constant-currency revenue growth guidance to 6.5%–8.0% and lifted full-year adjusted EPS outlook to $14.40–$14.60.

Shares of Waters Corp (NYSE:WAT) advanced sharply on Tuesday, climbing 11.1% to $335.39 after the lab equipment manufacturer released first-quarter results that topped consensus and prompted an upward revision to its full-year outlook.

For the quarter, Waters reported revenue of $1.27 billion, ahead of the $1.20 billion consensus compiled by LSEG. Company commentary attributed the top-line gain to robust organic performance and to contributions from the business it acquired from Becton Dickinson (NYSE:BDX).

On a per-share basis, adjusted earnings were $2.70 for the quarter, a 20% increase from the prior year and above the $2.34 per-share estimate from analysts. The stronger profit performance and the revenue beat combined to drive the sizable intraday move in Waters stock.

Following the quarterly results, management raised its 2026 outlook for organic constant-currency revenue growth to a range of 6.5% to 8.0%. The company also lifted its full-year adjusted profit forecast to $14.40 to $14.60 per share, up from the prior range of $14.30 to $14.50. Analysts had been modeling adjusted EPS of $14.38 for the year.

Market commentary highlighted the report as a confirmation point for Waters' recent strategic moves. Jefferies analyst Tycho Peterson said, "We view Q1 results as a solid proof point and likely major clearing event for those still skeptical on the deal." That remark emphasized the role the acquisition-related business is already playing in the company’s results.

Despite the rally on Tuesday, Waters shares remain roughly 11% below where they started the year. The stock’s year-to-date decline indicates that, even after a strong quarter and a raised outlook, investor sentiment toward the company has not fully reversed.


What the results make clear is that Waters reported a quarter of both top-line and adjusted-profit outperformance, and that management has moved guidance higher on the back of that performance and acquisition contributions. The company balanced a notable earnings beat with an upgraded revenue-growth target and a modest increase to full-year profit expectations.

Risks

  • Shares remain down about 11% year-to-date, indicating lingering investor caution despite the quarter’s strength - this affects equity market sentiment in the healthcare/equipment sector.
  • Forward-looking guidance is inherently uncertain and may change as future results are reported - this introduces forecasting risk for investors and analysts.
  • A portion of the revenue increase was attributed to contributions from the acquired Becton Dickinson business, which creates dependence on integration performance and sustained contribution from that unit.

More from Stock Markets

Criteo Extends ChatGPT Ad Integration as Shares Tick Higher May 5, 2026 Short Interest Climbs as Nike Struggles to Rebuild Momentum Under CEO Hill May 5, 2026 Microchip Technology Climbs Toward Yearly High as Analysts Lift Targets Ahead of Q4 Results May 5, 2026 Marvell Rallies After UBS Boosts Price Target to $195, Citing AI Data Center Strength May 5, 2026 Apimeds Pharma Stock Surges After Settlement Clears Path for Merger and PIPE May 5, 2026